Litcius/Paper detail

Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy

Jun Young Hong, Hui Jing, Ian R. Price, Ji Cao, Jessica Jingyi Bai, Hening Lin

2020ACS Medicinal Chemistry Letters55 citationsDOIOpen Access PDF

Abstract

As a member of the sirtuin family of enzymes, SIRT2 promotes tumor growth and regulates various biological pathways through lysine deacetylation and defatty-acylation. In the past few years, many SIRT2-selective small molecule inhibitors have been developed, but none have demonstrated simultaneous inhibition of both SIRT2 activities in cells. To further scrutinize the physiological importance and significance of SIRT2 deacetylase and defatty-acylase activities, small molecules that can selectively inhibit both activities of SIRT2 in living cells are needed. Here, we have applied the Proteolysis Targeting Chimera (PROTAC) strategy and synthesized a new SIRT2 inhibitor (TM-P4-Thal) to degrade SIRT2 selectively, which led to simultaneous inhibition of its deacetylase and defatty-acylase activities in living cells. Additionally, this compound exemplifies the advantage of the PROTAC strategy that allows complete eradication of an enzyme and its activity in biological settings.

Topics & Concepts

SIRT2SirtuinAcetylationLysineEnzymeChemistrySmall moleculeBiochemistryProteolysisHistone deacetylaseComputational biologyCell biologyBiologyAmino acidHistoneGeneProtein Degradation and InhibitorsUbiquitin and proteasome pathwaysSirtuins and Resveratrol in Medicine